- Our LinkedIn Page
- Our Twitter Feed
- Our Facebook Page
- Newsletter Subscribe to our e-newsletter. Current Issue
- Our Flickr Feed
- Our YouTube Feed
Tags
National Institutes of Health India United States Patent and Trademark Office PTO Gene Patents 2012 BIO International Convention BIO patent AUTM innovation USPTO biotechnology vaccines BIO International Convention Intellectual Property Technology Transfer Patent Reform drug development BIO Investor Forum NIHAuthors
- Abigail Hirsch
- Alan Eisenberg
- BIOtechNOW Editor
- Bruce Dale
- Celia Economides
- Colleen Lerro
- David Thomas, CFA
- George Goodno
- George MacDougall
- Jason Corum
- Jeff Joseph
- Jim Greenwood
- Karen Batra
- Kelly Cappio
- Lila Feisee
- Matt Carr
- Nathan Schock
- Paul Winters
- Paulina Ibarra
- Robbi Lycett
- Roy Zwahlen
- Sarah Sneeringer
- Sondra Behan
- Stephanie Fischer
- Stephen Marmaras
- Tracy Cooley
Archive
- May 2012 (3)
- April 2012 (3)
- March 2012 (4)
- February 2012 (6)
- January 2012 (2)
- December 2011 (2)
- November 2011 (3)
- October 2011 (3)
- September 2011 (5)
- August 2011 (4)
- July 2011 (8)
- June 2011 (16)
- May 2011 (8)
- April 2011 (9)
- March 2011 (14)
- February 2011 (9)
- January 2011 (15)
- December 2010 (7)
- November 2010 (6)
- October 2010 (4)
- June 2010 (1)
- May 2010 (4)
- April 2010 (14)
- March 2010 (4)
- January 2010 (5)
- November 2009 (3)
- October 2009 (1)
- August 2009 (6)
- July 2009 (9)
- June 2009 (9)
- May 2009 (8)
- April 2009 (9)
- March 2009 (9)
- February 2009 (3)
- January 2009 (1)
- November 2008 (1)
Category Archives: Patently BIOtech
Data Protection, the Trans Pacific Partnership, and the US-Jordan FTA (Post 1 of 2)
The Trans Pacific Partnership (TPP) negotiation does not yet include a section on data protection (typically included in the Pharmaceutical Chapter of Free Trade Agreements). Organizations against the inclusion of data protection in the TPP cite as evidence an Oxfam International study titled “All Costs, No Benefits: How TRIPS-plus intellectual property rules in the US-Jordan FTA affect access to medicines.” The Oxfam paper concludes that “medicine prices have increased drastically, and TRIPS-plus rules were partly Read More >
Non-Communicable Diseases and IP?
On September 19 and 20, the United Nations meets to potentially adopt a declaration on non-communicable diseases similar to the 2001 Declaration of Commitment on HIV/AIDS. The diseases of particular focus include cardiovascular disease, diabetes, cancer, and respiratory disease. Similar to previous UN initiatives around HIV/AIDS, the meeting will focus on developmental, social and economic impacts and other challenges, particularly for developing countries. UN background documents mention IP and it is possible that UN negotiations may Read More >
Tech Transfer Summit North America
The National Institutes of Health, BIO, and others are sponsoring the Tech Transfer Summit North America at NIH on 3-4 October 2011. Programming includes Translational Medicine & Funding Innovation, Successful Implementation of Biotech Innovation Strategies Worldwide, and Building Better Academia-Industry Collaborations: How will Big Pharma fill its early-stage Pipeline in 5 years’ time, among other topics. BIO’s President and CEO James C. Greenwood will give one keynote speach on the ”Barriers to Innovation in biotechnology, and Read More >
Biotechnology Patenting in Europe Event
BIO hosted a Biotechnology Patenting in Europe event last week here at BIO’s offices where attorneys from Carpmaels and Ransford addressed various issues of interest to U.S. biotechnology companies. Huw Halleybone discussed the relative challenges of patent harmonization in Europe quoting some reports that indicate that the cost of a European patent is 10 times the amount of the United States. Most of this cost is mainly due to language translation requirements and renewal fees. Read More >
Patent Reform Inches Closer to Becoming Law
Yesterday, Senate Majority Leader Harry Reid (D-NV) filed for cloture for The Leahy-Smith America Invents Act, H.R. 1249, bringing it one step closer to becoming law. When the Senate reconvenes in September, patent reform will be at the top of the agenda. In his comments on the Congressional compromise on the debt ceiling, President Obama included patent reform in the list of action needed to stimulate the economy and create jobs: “Through patent reform, we Read More >
